Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 34

References for PMC Articles for PubMed (Select 23475451)

1.

Prevention of HIV-1 infection with early antiretroviral therapy.

Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Mehendale S, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Wang L, Makhema J, Mills LA, de Bruyn G, Sanne I, Eron J, Gallant J, Havlir D, Swindells S, Ribaudo H, Elharrar V, Burns D, Taha TE, Nielsen-Saines K, Celentano D, Essex M, Fleming TR; HPTN 052 Study Team.

N Engl J Med. 2011 Aug 11;365(6):493-505. doi: 10.1056/NEJMoa1105243. Epub 2011 Jul 18.

2.

Receipt of preventive medical care and medical screening for patients with mental illness: a comparative analysis.

Lord O, Malone D, Mitchell AJ.

Gen Hosp Psychiatry. 2010 Sep-Oct;32(5):519-43. doi: 10.1016/j.genhosppsych.2010.04.004. Epub 2010 Aug 5. Review.

PMID:
20851274
3.

Assessing the STIRR model of best practices for blood-borne infections of clients with severe mental illness.

Rosenberg SD, Goldberg RW, Dixon LB, Wolford GL, Slade EP, Himelhoch S, Gallucci G, Potts W, Tapscott S, Welsh CJ.

Psychiatr Serv. 2010 Sep;61(9):885-91. doi: 10.1176/appi.ps.61.9.885.

4.

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.

Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N, Rossaro L, Anderson FH, Jacobson IM, Rubin R, Koury K, Pedicone LD, Brass CA, Chaudhri E, Albrecht JK; SPRINT-1 investigators.

Lancet. 2010 Aug 28;376(9742):705-16. doi: 10.1016/S0140-6736(10)60934-8. Epub 2010 Aug 6. Erratum in: Lancet. 2010 Oct 9;376(9748):1224. SPRINT-1 investigators [added]; multiple investigator names added.

PMID:
20692693
5.

Improving the Quality of Health Care for Mental and Substance-Use Conditions: Quality Chasm Series.

Institute of Medicine (US) Committee on Crossing the Quality Chasm: Adaptation to Mental Health and Addictive Disorders.

Washington (DC): National Academies Press (US); 2006.

6.

Recent advances in hepatitis C virus treatment: review of HCV protease inhibitor clinical trials.

Chary A, Holodniy M.

Rev Recent Clin Trials. 2010 Sep;5(3):158-73. Review.

PMID:
20482493
7.

Current strategies and barriers in integrated health care: a survey of publicly funded providers in Texas.

Sanchez K, Thompson S, Alexander L.

Gen Hosp Psychiatry. 2010 Jan-Feb;32(1):26-32. doi: 10.1016/j.genhosppsych.2009.10.007. Epub 2009 Dec 2.

PMID:
20114125
8.

The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements.

Dixon LB, Dickerson F, Bellack AS, Bennett M, Dickinson D, Goldberg RW, Lehman A, Tenhula WN, Calmes C, Pasillas RM, Peer J, Kreyenbuhl J; Schizophrenia Patient Outcomes Research Team (PORT).

Schizophr Bull. 2010 Jan;36(1):48-70. doi: 10.1093/schbul/sbp115. Epub 2009 Dec 2. Review.

9.

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.

McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, Alam J, Muir AJ; PROVE1 Study Team.

N Engl J Med. 2009 Apr 30;360(18):1827-38. doi: 10.1056/NEJMoa0806104. Erratum in: N Engl J Med. 2009 Oct 8;361(15):1516.

10.

Effects of a nurse-managed program on hepatitis A and B vaccine completion among homeless adults.

Nyamathi A, Liu Y, Marfisee M, Shoptaw S, Gregerson P, Saab S, Leake B, Tyler D, Gelberg L.

Nurs Res. 2009 Jan-Feb;58(1):13-22. doi: 10.1097/NNR.0b013e3181902b93.

11.

Cost-effectiveness analysis of behavioral interventions to improve vaccination compliance in homeless adults.

Greengold B, Nyamathi A, Kominski G, Wiley D, Lewis MA, Hodge F, Singer M, Spiegel B.

Vaccine. 2009 Jan 29;27(5):718-25. doi: 10.1016/j.vaccine.2008.11.031. Epub 2008 Nov 27.

12.

Hepatitis C services and individuals with serious mental illness.

Goldberg RW, Seth P.

Community Ment Health J. 2008 Oct;44(5):381-4. doi: 10.1007/s10597-008-9140-0. Epub 2008 May 9.

PMID:
18465227
13.

The cost-effectiveness of testing for hepatitis C in former injecting drug users.

Castelnuovo E, Thompson-Coon J, Pitt M, Cramp M, Siebert U, Price A, Stein K.

Health Technol Assess. 2006 Sep;10(32):iii-iv, ix-xii, 1-93.

14.
15.

Cost effectiveness of hepatitis B vaccination at HIV counseling and testing sites.

Kim SY, Billah K, Lieu TA, Weinstein MC.

Am J Prev Med. 2006 Jun;30(6):498-506.

PMID:
16704944
16.

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002.

Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ.

Ann Intern Med. 2006 May 16;144(10):705-14.

PMID:
16702586
17.

Hepatitis B vaccination coverage among adults--United States, 2004.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2006 May 12;55(18):509-11.

18.

Hepatitis C treatment for people with severe mental illness.

Mistler LA, Brunette MF, Marsh BJ, Vidaver RM, Luckoor R, Rosenberg SD.

Psychosomatics. 2006 Mar-Apr;47(2):93-107. Review.

PMID:
16508020
19.

Predictors of HIV and hepatitis testing and related service utilization among individuals with serious mental illness.

Goldberg RW, Himelhoch S, Kreyenbuhl J, Dickerson FB, Hackman A, Fang LJ, Brown CH, Wohlheiter KA, Dixon LB.

Psychosomatics. 2005 Nov-Dec;46(6):573-7.

PMID:
16288138
20.

Hepatitis C virus and HIV co-infection in people with severe mental illness and substance use disorders.

Rosenberg SD, Drake RE, Brunette MF, Wolford GL, Marsh BJ.

AIDS. 2005 Oct;19 Suppl 3:S26-33.

PMID:
16251824
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk